NEW YORK (GenomeWeb News) – PerkinElmer said today that it has received Clinical Laboratory Improvement Amendments certification and a license from the State of Connecticut for its DNA Sequencing Services Laboratory in Branford.
PerkinElmer said that certification will enable it to expand its offerings to include clinical sequencing services for analysis of specific diseases including cancer and Mendelian diseases, as well as diagnostics services for new drugs and for pharmaceutical clinical trial studies.
"The tests performed at the next generation sequencing laboratory include DNA exome and targeted sequencing as well as RNA sequencing," Richard Begley, president of emerging technologies at PerkinElmer, said in a statement. "PerkinElmer's objective is to offer the broadest array of genomic and proteomic diagnostics as well as tools for more efficient research and drug discovery."
PerkinElmer's services portfolio includes DNA/RNA extraction; high-throughput plate reader assessment of DNA quantity and quality; statistical visualization and annotation tools for microarray and next-gen sequencing data; library preparation with liquid handling; as well as sequencing and analysis services.